PURPOSE: Examine incidence and factors associated with loss to follow-up (LTFU) in the AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) cohort. METHOD:ALLRT is a prospective cohort of HIV-infected persons randomized to antiretroviral (ARV) regimens/strategies in ACTG trials and followed long-term after the trial ends. Person-years were calculated from ALLRT entry until loss to follow-up (LTFU; defined using off-study reasons or ≥ 3 consecutive missed visits), death/ severe debilitation/site closures, or June 2009 (censored). Poisson regression was used to examine LTFU factors separately among participants who were ARV naïve or ARV experienced at trial entry. RESULTS: Among 4,630 participants (22,524 person-years), 1,140 were lost to follow-up, 237 died, 29 were severely debilitated, and 443 were at sites that closed. The LTFU incidence was 5.5 and 4.2 per 100 person-years among previously ARV-naïve and ARV-experienced participants, respectively. In both groups, age ≤ 50, site location, being off ARVs, and viral load ≥ 400 copies/mL were associated with a higher risk of LTFU. Among ARV-naïve participants, male sex, education <16 years, intravenous drug use, and cigarette smoking were also associated with LTFU. CONCLUSION: Knowledge of differential LTFU can help researchers identify participants at risk of LTFU in longitudinal HIV cohorts and design retention strategies, thereby limiting study bias. The identified factors should be included in inverse probability of weighting models to account for LTFU.
RCT Entities:
PURPOSE: Examine incidence and factors associated with loss to follow-up (LTFU) in the AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) cohort. METHOD: ALLRT is a prospective cohort of HIV-infectedpersons randomized to antiretroviral (ARV) regimens/strategies in ACTG trials and followed long-term after the trial ends. Person-years were calculated from ALLRT entry until loss to follow-up (LTFU; defined using off-study reasons or ≥ 3 consecutive missed visits), death/ severe debilitation/site closures, or June 2009 (censored). Poisson regression was used to examine LTFU factors separately among participants who were ARV naïve or ARV experienced at trial entry. RESULTS: Among 4,630 participants (22,524 person-years), 1,140 were lost to follow-up, 237 died, 29 were severely debilitated, and 443 were at sites that closed. The LTFU incidence was 5.5 and 4.2 per 100 person-years among previously ARV-naïve and ARV-experienced participants, respectively. In both groups, age ≤ 50, site location, being off ARVs, and viral load ≥ 400 copies/mL were associated with a higher risk of LTFU. Among ARV-naïve participants, male sex, education <16 years, intravenous drug use, and cigarette smoking were also associated with LTFU. CONCLUSION: Knowledge of differential LTFU can help researchers identify participants at risk of LTFU in longitudinal HIV cohorts and design retention strategies, thereby limiting study bias. The identified factors should be included in inverse probability of weighting models to account for LTFU.
Authors: Katia Prime; Gulshan Sethi; Leslie Navaratne; Gill Dean; Emma Fox; Caroline Sabin; Chris Taylor; Annemiek de Ruiter; Graham Taylor; Simon Edwards Journal: AIDS Date: 2003-01-24 Impact factor: 4.177
Authors: Thomas P Giordano; Allen L Gifford; A Clinton White; Maria E Suarez-Almazor; Linda Rabeneck; Christine Hartman; Lisa I Backus; Larry A Mole; Robert O Morgan Journal: Clin Infect Dis Date: 2007-04-23 Impact factor: 9.079
Authors: B Lebouché; Y Yazdanpanah; Y Gérard; D Sissoko; F Ajana; I Alcaraz; P Boitte; B Cadoré; Y Mouton Journal: HIV Med Date: 2006-04 Impact factor: 3.180
Authors: Kristine M Erlandson; Jeremiah Perez; Mona Abdo; Kevin Robertson; Ronald J Ellis; Susan L Koletar; Robert Kalayjian; Babafemi Taiwo; Frank J Palella; Katherine Tassiopoulos Journal: Clin Infect Dis Date: 2019-01-01 Impact factor: 9.079
Authors: Judith J Lok; Peter W Hunt; Ann C Collier; Constance A Benson; Mallory D Witt; Amneris E Luque; Steven G Deeks; Ronald J Bosch Journal: AIDS Date: 2013-08-24 Impact factor: 4.177
Authors: Leslie A Bruggeman; John F O'Toole; Michael D Ross; Sethu M Madhavan; Marlene Smurzynski; Kunling Wu; Ronald J Bosch; Samir Gupta; Martin R Pollak; John R Sedor; Robert C Kalayjian Journal: J Am Soc Nephrol Date: 2013-11-14 Impact factor: 10.121
Authors: Peter F Rebeiro; Alison G Abraham; Michael A Horberg; Keri N Althoff; Baligh R Yehia; Kate Buchacz; Bryan M Lau; Timothy R Sterling; Stephen J Gange Journal: AIDS Patient Care STDS Date: 2017-02-27 Impact factor: 5.078
Authors: Marlene Smurzynski; Kunling Wu; Jeffrey T Schouten; Judith J Lok; Ronald J Bosch; Babafemi Taiwo; Victoria Anne Johnson; Ann C Collier Journal: AIDS Date: 2013-07-31 Impact factor: 4.177
Authors: Kathryn B Arnold; John A Hermos; Karen B Anderson; Lori Minasian; Catherine M Tangen; Jeffrey F Probstfield; Elise D Cook Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-09-21 Impact factor: 4.254
Authors: T Kiriazova; D M Cheng; S M Coleman; E Blokhina; E Krupitsky; M C Lira; C Bridden; A Raj; J H Samet Journal: HIV Clin Trials Date: 2014 May-Jun